Park S, Baldry R, Jung HA, Sun JM, et al. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM). J Clin Oncol 2024 Jun 3:JCO2400708. doi: 10.1200/JCO.24.00708.
PMID: 38828959